| ILA | insulin-like activity; International Leprosy Association |
|---|---|
| ILGF | insulin-like growth factor |
| ILM | insulin-like material; internal limiting membrane |
| IMI | immunologically measurable insulin; impending myocardial infarction; Imperial Mycological Institute ... |
| IN | icterus neonatorum; impetigo neonatorum; incidence; incompatibility number; infundibular nucleus; in... |
| IGFBP-3 | Insulin-like growth factor binding protein-3 |
|---|---|
| IGFBP-1 | Insulin-like growth factor (IGF)-binding protein 1 |
| IGFBP-3 | Insulin-like growth factor (IGF)-binding protein-3 |
| IGF-BP | insulin-like growth factor I and its binding protein |
| IGFR | Insulin-like growth factor I receptor |
| insulinopenic |
pertaining to or characterized by hypoinsulinism.
출처: www.mercksource.com/pp/us/cns/cns_health_library.j...
|
|---|---|
| insulin analogue |
Any synthetic insulin in which small changes in the amino acid structure of the polypeptide result in changes in the onset, peak effect, or duration of the molecule's physiological effects. Insulin aspart, glargine, and lispro a
출처:
|
| insulin aspart |
A rapidly acting insulin administered subcutaneously, with action similar to that of insulin lispro. Aspartic acid replaces proline at a crucial position in the insulin molecule.
출처:
|
| insulin glargine |
A very slow acting insulin administered subcutaneously that provides basal insulin coverage. It is made by changing the glycine and arginine content of the insulin polypeptide.
출처:
|
| insulin injection site |
The places on the body that are suitable for injecting insulin. Because insulin is administered at least once daily, it is important to have a plan for selecting the site. The best sites for insulin injection are in the su
출처:
|